Skip to main content
Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · IEX Real-Time Price · USD
1,063.60
-3.66 (-0.34%)
At close: Jul 19, 2024, 4:00 PM
1,081.87
+18.27 (1.72%)
Pre-market: Jul 22, 2024, 7:29 AM EDT

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 24 analysts with 12-month price forecasts for REGN stock have an average target of 1,055, with a low estimate of 720 and a high estimate of 1,229. The average target predicts a decrease of -0.84% from the current stock price of 1,063.60.

Analyst Consensus: Buy
Target Low Average Median High
Price $720 $1,055 $1,125 $1,229
Change -32.31% -0.84% +5.77% +15.55%

Analyst Ratings

The average analyst rating for REGN stock from 24 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Feb '24Mar '24Apr '24May '24Jun '24Jul '24
Strong Buy 778777
Buy 121310111212
Hold 445554
Sell 111111
Strong Sell 000000
Total 242524242524

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Christopher Raymond
Piper Sandler
 Piper Sandler
Buy
Maintains
$1,000 → $1,166
 Buy Maintains $1,000 → $1,166 +9.63% Jul 19, 2024
Yatin Suneja
Guggenheim
 Guggenheim
Strong Buy
Maintains
$1,040 → $1,180
 Strong Buy Maintains $1,040 → $1,180 +10.94% Jul 18, 2024
Matthew Harrison
Morgan Stanley
 Morgan Stanley
Buy
Maintains
$1,183 → $1,182
 Buy Maintains $1,183 → $1,182 +11.13% Jul 11, 2024
Carter Gould
Barclays
 Barclays
Buy
Maintains
$1,050 → $1,200
 Buy Maintains $1,050 → $1,200 +12.82% Jul 10, 2024
John Newman
Canaccord Genuity
 Canaccord Genuity
Strong Buy
Maintains
$1,152
 Strong Buy Maintains $1,152 +8.31% Jun 27, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
14.10B
from 13.12B
Increased by 7.52%
Revenue Next Year
15.26B
from 14.10B
Increased by 8.16%
EPS This Year
45.02
from 34.77
Increased by 29.47%
EPS Next Year
48.90
from 45.02
Increased by 8.64%
Year 2019202020212022202320242025202620272028
Revenue
6.56B8.50B16.07B12.17B13.12B14.10B15.26B16.37B17.88B18.94B
Revenue Growth
27.44%29.58%89.14%-24.26%7.76%7.52%8.16%7.34%9.18%5.97%
EPS
18.4630.5271.9738.2234.7745.0248.9053.9961.4867.00
EPS Growth
-13.29%65.33%135.81%-46.89%-9.03%29.47%8.64%10.41%13.86%8.98%
Forward PE
-----23.6321.7519.7017.3015.88
No. Analysts -----3131261616
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20242025202620272028
High 15.1B 17.7B 19.4B 21.2B 22.3B
Avg 14.1B 15.3B 16.4B 17.9B 18.9B
Low 13.0B 13.6B 13.4B 14.6B 14.9B

Revenue Growth

Revenue Growth 20242025202620272028
High
15.5%
25.5%
27.1%
29.7%
25.0%
Avg
7.5%
8.2%
7.3%
9.2%
6.0%
Low
-0.7%
-3.3%
-12.2%
-11.0%
-16.9%

EPS Forecast

EPS 20242025202620272028
High 54.11 64.44 74.56 75.79 81.78
Avg 45.02 48.90 53.99 61.48 67.00
Low 38.04 40.18 40.33 45.79 48.09

EPS Growth

EPS Growth 20242025202620272028
High
55.6%
43.1%
52.5%
40.4%
33.0%
Avg
29.5%
8.6%
10.4%
13.9%
9.0%
Low
9.4%
-10.7%
-17.5%
-15.2%
-21.8%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.